These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26041300)

  • 21. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
    Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.
    Bomsel M; Tudor D; Drillet AS; Alfsen A; Ganor Y; Roger MG; Mouz N; Amacker M; Chalifour A; Diomede L; Devillier G; Cong Z; Wei Q; Gao H; Qin C; Yang GB; Zurbriggen R; Lopalco L; Fleury S
    Immunity; 2011 Feb; 34(2):269-80. PubMed ID: 21315623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIV
    Dias J; Fabozzi G; Fourati S; Chen X; Liu C; Ambrozak DR; Ransier A; Laboune F; Hu J; Shi W; March K; Maximova AA; Schmidt SD; Samsel J; Talana CA; Ernste K; Ko SH; Lucas ME; Radecki PE; Boswell KL; Nishimura Y; Todd JP; Martin MA; Petrovas C; Boritz EA; Doria-Rose NA; Douek DC; Sékaly RP; Lifson JD; Asokan M; Gama L; Mascola JR; Pegu A; Koup RA
    Nat Commun; 2024 Aug; 15(1):7461. PubMed ID: 39198422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.
    Liu J; Ghneim K; Sok D; Bosche WJ; Li Y; Chipriano E; Berkemeier B; Oswald K; Borducchi E; Cabral C; Peter L; Brinkman A; Shetty M; Jimenez J; Mondesir J; Lee B; Giglio P; Chandrashekar A; Abbink P; Colantonio A; Gittens C; Baker C; Wagner W; Lewis MG; Li W; Sekaly RP; Lifson JD; Burton DR; Barouch DH
    Science; 2016 Sep; 353(6303):1045-1049. PubMed ID: 27540005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
    Lin A; Balazs AB
    Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple Combinations of AAV9-Vectors Encoding Anti-HIV bNAbs Provide Long-Term In Vivo Expression of Human IgG Effectively Neutralizing Pseudoviruses from HIV-1 Global Panel.
    Shipulin GA; Glazkova DV; Urusov FA; Belugin BV; Dontsova V; Panova AV; Borisova AA; Tsyganova GM; Bogoslovskaya EV
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.
    Shingai M; Donau OK; Plishka RJ; Buckler-White A; Mascola JR; Nabel GJ; Nason MC; Montefiori D; Moldt B; Poignard P; Diskin R; Bjorkman PJ; Eckhaus MA; Klein F; Mouquet H; Cetrulo Lorenzi JC; Gazumyan A; Burton DR; Nussenzweig MC; Martin MA; Nishimura Y
    J Exp Med; 2014 Sep; 211(10):2061-74. PubMed ID: 25155019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure.
    Suphaphiphat K; Desjardins D; Lorin V; Dimant N; Bouchemal K; Bossevot L; Galpin-Lebreau M; Dereuddre-Bosquet N; Mouquet H; Le Grand R; Cavarelli M
    Nat Commun; 2023 Oct; 14(1):6224. PubMed ID: 37803011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus.
    Egan MA; Chong SY; Megati S; Montefiori DC; Rose NF; Boyer JD; Sidhu MK; Quiroz J; Rosati M; Schadeck EB; Pavlakis GN; Weiner DB; Rose JK; Israel ZR; Udem SA; Eldridge JH
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):629-43. PubMed ID: 16060834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly neutralizing antibody-mediated protection against simian-HIV infection among macaques with vaginal sexually transmitted infections.
    Garber DA; Guenthner P; Zhao C; Mitchell J; Ellis S; Jia H; Manganare M; Gazumyan A; Seaman MS; Vishwanathan SA; Heneine W; McNicholl JM
    AIDS; 2023 Apr; 37(5):723-731. PubMed ID: 36625252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
    Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
    J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
    Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z; Li J; Hu X; Shao Y; Zhang MY
    Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.
    Foresman L; Jia F; Li Z; Wang C; Stephens EB; Sahni M; Narayan O; Joag SV
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1035-43. PubMed ID: 9718118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.
    Ferrantelli F; Rasmussen RA; Buckley KA; Li PL; Wang T; Montefiori DC; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM
    J Infect Dis; 2004 Jun; 189(12):2167-73. PubMed ID: 15181562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection.
    Yamamoto T; Lynch RM; Gautam R; Matus-Nicodemos R; Schmidt SD; Boswell KL; Darko S; Wong P; Sheng Z; Petrovas C; McDermott AB; Seder RA; Keele BF; Shapiro L; Douek DC; Nishimura Y; Mascola JR; Martin MA; Koup RA
    Sci Transl Med; 2015 Jul; 7(298):298ra120. PubMed ID: 26223303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vector-mediated antibody gene transfer for infectious diseases.
    Schnepp BC; Johnson PR
    Adv Exp Med Biol; 2015; 848():149-67. PubMed ID: 25757620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.